| | | |  | Cancer Briefing will return in your inbox on Tuesday, Jan. 3. | | | | By Jason Mast Chantal Heijnen for STAT The interest is in Tmunity's leukemia and lymphoma programs, as well as technology that could speed up CAR-T manufacturing. Read More | | By Adam Feuerstein Andy Wong/AP The Phase 2 study results from Gilead and Arcus could augur a comeback of sorts for the entire class of TIGIT-targeted antibody treatments. Read More | | By Jonathan Wosen Gillian Flaccus/AP A massive trial returned results good enough for Medicare reimbursement, but underperformed earlier, smaller studies. Read More | | Sponsored Insight by Hologic Cervical cancer rates nearly 1.5 times higher in Hispanic women than white women, NIH reports Despite progress in identifying and treating cancers early and effectively, cervical cancer incidence rates have been trending in the wrong direction for the past decade, according to NIH's Surveillance, Epidemiology, and End Results Program. Women of color, particularly Hispanic women, have been hardest hit – for Hispanic women, the rate is 10.3/100,000, compared to just 7.0/100,000 for white women. Learn how Hologic is working to increase access to testing and diagnosis for all women. | | By Damian Garde and Angus Chen Join STAT for a discussion of the most prominent work presented at ASH 2022 and a look at what's coming in hematology in the year ahead. Read More | |
No comments